Table 2.
Changes in clinical, sacubitril/valsartan dose, biochemical and echocardiographic parameters.
| Baseline | Follow-up | p Value | |
|---|---|---|---|
| SBP (mmHg) | 118.5 ± 15 | 115.4 ± 16.9 | 0.042 |
| DBP (mmHg) | 73 ± 10.3 | 67.5 ± 9.3 | <0.001 |
| NT-proBNP (pg/mL) | 1865 ± 2318 | 1514 ± 2205 | 0.01 |
| Creatinine (mg/dL) | 1.2 ± 0.35 | 1.31 ± 0.57 | 0.052 |
| eGFR (mL/min/1.73 m2) | 69.4 ± 23.1 | 65.3 ± 23.2 | 0.012 |
| potassium (mEq/L) | 4.14 ± 0.44 | 4.17 ± 0.44 | 0.611 |
| Furosemide dose (mg) | 131.3 ± 154.5 | 120 ± 142.5 | 0.047 |
| SACUBITRIL/VALSARTAN | |||
| 24/26 (mg/bid) | 77 | 39 | |
| 49/51 (mg/bid) | 23 | 34 | |
| 97/103 (mg/bid) | 0 | 27 | |
| FE (%) | 27 ± 5.9 | 30 ± 7.7 | <0.001 |
| EDVi (mL/m2) | 120.5 ± 31.4 | 120.7 ± 33 | 0.932 |
| MR mod/sev (%) | 30.1 | 17.4 | 0.002 |
| E/A | 1.67 ± 1.21 | 1.42 ± 1.12 | 0.002 |
| E/e’ | 14.79 ± 6.10 | 13.85 ± 6.09 | 0.194 |
| LAVi (mL/m2) | 54.2 ± 22.6 | 52.4 ± 19.1 | 0.202 |
| TR velocity (m/s) | 2.8 ± 0.55 | 2.64 ± 0.59 | 0.014 |
| TAPSE (mm) | 19.03 ± 4.55 | 19.28 ± 3.62 | 0.472 |
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; Nt-proBNP, N-terminal pro–B-type natriuretic peptide. eGFR, estimated glomerular filtration rate; EF, ejection fraction; EDVi, endiastolic volume index.; MR, mitral regurgitation from moderate to severe grade; E/A: peak e-wave velocity/peak a-wave velocity ratio; E/e’ peak: e-wave velocity divided by mitral annular e’ velocity (average) ratio; LAV-i, left atrial volume index; RA, right atrium; TR velocity: tricuspid regurgitation peak velocity; TAPSE, tricuspid annular plane systolic excursion.